Basel, Switzerland – In a significant advancement in the fight against tuberculosis (TB), BioVersys AG has announced the publication of Phase 2a trial results for its novel therapeutic combination, alpibectir (AlpE) and ethionamide, in the prestigious Modern England Journal of Medicine. The findings demonstrate the first clinical proof of concept for AlpE, offering a potential new strategy to combat the growing threat of drug-resistant TB, a disease that remains one of the world’s leading causes of infectious disease mortality.
The study, conducted in South Africa in collaboration with TASK and GSK, confirmed the promising early bactericidal activity of AlpE. Researchers found that the combination demonstrated efficacy in reducing the bacterial load in patients with pulmonary tuberculosis over a seven-day period. This early success suggests AlpE could potentially serve as an alternative to isoniazid, a first-line TB treatment, or be incorporated into future TB treatment regimens, including those targeting the more severe form of the disease, tuberculous meningitis.
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, continues to pose a major global health challenge. According to the World Health Organization, an estimated 7.6 million people fell ill with TB in 2021, and approximately 1.6 million died. WHO The rise of multidrug-resistant (MDR) strains further complicates treatment, necessitating the development of new and effective therapies.
Alpibectir: A Novel Approach to Overcoming Drug Resistance
Alpibectir, a minor molecule developed through a collaborative effort between BioVersys, GSK, the Pasteur Institute Lille, and the University of Lille, works through a novel mechanism of action. It’s designed to significantly enhance the activity of ethionamide, an existing antibiotic, effectively overcoming resistance mechanisms. This approach, known as potentiation, aims to revitalize older drugs and extend their usefulness in the face of increasing resistance. The development of Alpibectir was also supported by a 6.92 million EUR grant from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) through the TRIC-TB project. New TB Drugs
Phase 2a Trial Details and Future Directions
The Phase 2a bEto-TB clinical trial, completed in April 2024, involved patients with pulmonary tuberculosis. The results, published on February 19, 2026, Yahoo Finance underscore the potential of AlpE to reshape TB treatment strategies. BioVersys AG, trading on the SIX Swiss Exchange under the ticker BIOV, is a multi-asset, clinical-stage biopharmaceutical company focused on developing antibacterial products for serious, life-threatening infections caused by MDR bacteria.
The U.S. Food and Drug Administration (FDA) previously granted orphan-drug designation to the alpibectir and ethionamide fixed-dose combination for the treatment of tuberculosis in December 2023, recognizing the urgent need for new therapies. BioVersys BioVersys also received orphan drug designation from the European Medicines Agency (EMA) in August 2025. eatg.org
Looking ahead, BioVersys plans to continue developing AlpE, exploring its potential in various TB treatment regimens and patient populations. The success of this Phase 2a trial represents a crucial step forward in the quest for more effective and accessible treatments for tuberculosis, particularly in regions with high rates of drug resistance and limited resources.
Disclaimer: This article provides informational content about medical research and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
What are your thoughts on this promising new development in TB treatment? Share your comments below, and please share this article with your network to raise awareness about the ongoing fight against tuberculosis.